The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.
For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Wilson Sonsini Advises Zipline on $1.5 Billion Funding Round
On November 5, 2026, Zipline announced a $1.5 billion raise at a $21.5 billion post-money valuation, led by Paradigm, WCM Investment Management, and Layer Global with participation from Valor Equity Partners, Fidelity Management & Research Company, Uber, Tiger Global, J.P. Morgan, ARK Invest, and Salesforce Ventures. Wilson Sonsini Goodrich & Rosati advised Zipline on the transaction.
Wilson Sonsini Advises Tigris Data on Acquisition by DropBox
On November 5, 2026, Dropbox announced plans to acquire Tigris Data, a globally distributed object storage platform built for AI workloads. Wilson Sonsini Goodrich & Rosati is advising Tigris Data on the transaction.
Client Highlights
Wilson Sonsini Advises FluoRok on Patent Matters Related to $30 Million Oversubscribed Series A
On November 5, 2026, FluoRok, a UK company building a manufacturing platform for fluorochemicals that does not require hydrogen fluoride, announced it closed an oversubscribed $30 million Series A financing round. The round was led by Orano Venture Fund/Supernova Invest, alongside investment from Bidra Innovation Ventures and existing investors Oxford Science Enterprises, BGF, GGF, Volta Energy Technologies, and the University of Oxford. Wilson Sonsini Goodrich & Rosati advised FluoRok on patent matters related to the financing.
Client Highlights
Firm Advises Marvell on $115 Billion Acquisition of Lumentum
On November 2, 2026, Marvell Technology, a leader in data infrastructure semiconductor solutions, announced that they have entered into a definitive agreement to acquire Lumentum, a global leader in optical and photonic technologies that power the networks and infrastructure behind artificial intelligence, cloud computing, and next-generation communications, in an all-stock transaction. Under the terms of the agreement, Lumentum stockholders will receive a fixed exchange ratio of 4.500 shares of Marvell common stock for each share of Lumentum common stock they own. The transaction has an implied enterprise value of $115 billion for Lumentum, representing approximately $1,132 per share of Lumentum common stock and a premium of approximately 23.9 percent based on each company’s unaffected closing share price as of October 28, 2026. Wilson Sonsini Goodrich & Rosati is advising Marvell on the transaction.
Client Highlights
Wilson Sonsini Advises Bambusa Therapeutics on $168.9 Million Initial Public Offering
On October 29, 2026, Bambusa Therapeutics, a Boston-based clinical-stage company developing next-generation, long-acting precision bispecific antibodies for immunology and inflammation, announced the pricing of its upsized initial public offering of 10,555,555 shares of its common stock at a public offering price of $16.00 per share. Bambusa’s common stock began trading on the Nasdaq Global Select Market today under the ticker symbol “BBTX.” Wilson Sonsini Goodrich & Rosati advised Bambusa on the transaction.
Client Highlights
Wilson Sonsini Advises GT Metabolic on Series C Growth Investment
On October 28, 2026, GT Metabolic™ Solutions, a pioneer in the medical device field and the first to receive FDA De Novo grant and 510(k) clearance for use of magnetic technology to create compression anastomoses (connections between two tubular structures in the body, such as intestines), announced a Series C growth investment from J.P. Morgan Life Sciences Private Capital. Wilson Sonsini Goodrich & Rosati advised GT Metabolic on the transaction.
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.